After finishing at $74.58 in the prior trading day, CVS Health Corp (NYSE: CVS) closed at $74.44, down -0.19%. In other words, the price has decreased by -$0.14 from its previous closing price. On the day, 6495351 shares were traded.
Ratios:
Our goal is to gain a better understanding of CVS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.01. For the most recent quarter (mrq), Quick Ratio is recorded 0.63 and its Current Ratio is at 0.86. In the meantime, Its Debt-to-Equity ratio is 1.04 whereas as Long-Term Debt/Eq ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Equal Weight rating and assigned the stock a target price of $78.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.
On December 22, 2023, HSBC Securities started tracking the stock assigning a Buy rating and target price of $94.HSBC Securities initiated its Buy rating on December 22, 2023, with a $94 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 ’24 when Shah Prem S sold 29,473 shares for $76.95 per share. The transaction valued at 2,267,947 led to the insider holds 39,765 shares of the business.
LUDWIG EDWARD J bought 2,000 shares of CVS for $140,930 on Nov 03 ’23. The Director now owns 20,630 shares after completing the transaction at $70.47 per share. On Aug 03 ’23, another insider, Clark James David, who serves as the SVP, Cont & Chief Acct Officer of the company, sold 25,759 shares for $74.92 each. As a result, the insider received 1,930,004 and left with 4,698 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVS now has a Market Capitalization of 93.83B and an Enterprise Value of 161.76B. As of this moment, CVS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.51, and their Forward P/E ratio for the next fiscal year is 8.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 1.25. Its current Enterprise Value per Revenue stands at 0.45 whereas that against EBITDA is 8.89.
Stock Price History:
Over the past 52 weeks, CVS has reached a high of $83.25, while it has fallen to a 52-week low of $64.41. The 50-Day Moving Average of the stock is 75.89, while the 200-Day Moving Average is calculated to be 72.71.
Shares Statistics:
The stock has traded on average 11.03M shares per day over the past 3-months and 9.79M shares per day over the last 10 days, according to various share statistics. A total of 1.29B shares are outstanding, with a floating share count of 1.26B. Insiders hold about 0.19% of the company’s shares, while institutions hold 82.36% stake in the company. Shares short for CVS as of Mar 15, 2024 were 18.64M with a Short Ratio of 1.69, compared to 30.76M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.48% and a Short% of Float of 1.48%.
Dividends & Splits
In the trailing 12 months, CVS’s forward annual dividend rate was 2.42, compared to 2.48 this year. Against a Trailing Annual Dividend Yield of 3.24%, it implies a Forward Annual Dividend Yield of 3.57%. The stock’s 5-year Average Dividend Yield is 2.86. The current Payout Ratio is 38.34% for CVS, which recently paid a dividend on May 01, 2024 with an ex-dividend date of Apr 19, 2024. Stock splits for the company last occurred on Jun 07, 2005 when the company split stock in a 2:1 ratio.
